rethinkPeptides Search
Menu
Study breakdown

Peptoids: The Indestructible Cousins of Peptides That Could Become Next-Generation Drugs

ReviewModerate evidence
The takeaway

Peptoids are synthetic peptide-like molecules that are completely immune to the enzymes that destroy natural peptides, making them promising candidates for drugs in areas from infection to cancer.

100% protease-resistant

Peptoids are completely resistant to protease degradation — the main reason natural peptides fail as drugs — due to their N-substituted glycine backbone

What the researchers found

Peptoids are synthetic molecules with a peptide-like backbone but with side chains attached to nitrogen instead of carbon, making them completely resistant to protease degradation — the main reason natural peptides break down so quickly in the body. Sequences up to 50 units long can be synthesized with precise control over composition and diverse side chain chemistry.

The review covers therapeutic applications across four areas: lung surfactant replacement therapy, antimicrobial agents, cancer therapeutics, and diagnostics. Peptoids have demonstrated bioactivity both as protein mimics and as replacements for small molecule drugs, with particular promise in lipid-associated applications where their protease resistance gives them a major advantage over natural peptides.

Why it matters

The biggest problem with peptide drugs is that the body destroys them within minutes. Peptoids solve this fundamental limitation by subtly rearranging the molecular structure to make it invisible to proteases while retaining peptide-like biological activity. If peptoids can replicate peptide functions with dramatically improved stability, they could unlock therapeutic applications that peptides alone cannot achieve.

The numbers in context

up to 50 units in length · complete protease resistance · invented early 1990s · N-substituted glycine backbone

How the study worked

Comprehensive review of peptoid research advances covering synthesis methods, structural characterization, and therapeutic applications in lung surfactant therapy, antimicrobial agents, cancer, and diagnostics, with emphasis on in vitro and in vivo studies.

Who was studied

Not applicable — review of peptoid research across multiple therapeutic areas

What this study cannot tell us

As a review, this synthesizes existing research without new experimental data. While peptoids show promise in multiple therapeutic areas, most applications remain preclinical. The structural landscape of peptoids is less well-defined than that of peptides, making rational design more challenging. The relationship between peptoid structure and biological function is still being elucidated.

How to read the evidence

This is a comprehensive review in Current Pharmaceutical Design covering peptoid synthesis, structure, and therapeutic applications. While it provides a thorough overview, most applications discussed are preclinical, and the field's maturity is moderate.

When this study was published

Published in 2011 in Current Pharmaceutical Design. Peptoid research has advanced significantly since publication — newer reviews may cover more recent clinical progress. However, the fundamental chemistry and design principles described remain valid.

The bigger picture

Peptoids represent one of several peptidomimetic strategies competing to solve the peptide stability problem. While other approaches like D-amino acids, cyclic peptides, and stapled peptides each offer partial solutions, peptoids' complete protease resistance is unique. If the structural design challenges can be overcome, peptoids could fill the gap between small molecule drugs (stable but limited targets) and peptide/protein biologics (versatile but fragile).

Questions still open

  • Which therapeutic application is closest to clinical trials for peptoid-based drugs?
  • How does the reduced structural predictability of peptoids compared to peptides affect rational drug design?
  • Can peptoids achieve oral bioavailability, or do they still face absorption challenges despite protease resistance?

Common questions

What's the difference between a peptide and a peptoid?
Both have a similar backbone structure, but in peptides the side chains attach to the alpha carbon, while in peptoids they attach to the nitrogen. This seemingly small change makes peptoids completely invisible to proteases — the enzymes that rapidly destroy natural peptides in the body.
Why aren't peptoid drugs available yet if they're so stable?
While protease resistance solves one major problem, designing peptoids with the right shape and biological activity is more challenging than with peptides. Peptoid structures are less predictable, making it harder to engineer specific functions. The field is advancing but still working through these design challenges before reaching clinical trials.

Read the original research

Peptoids: bio-inspired polymers as potential pharmaceuticals.

Current pharmaceutical design, 17(25), 2732-47

Citation

Dohm, Michelle T; Kapoor, Rinki; Barron, Annelise E. (2011). Peptoids: bio-inspired polymers as potential pharmaceuticals.. Current pharmaceutical design, 17(25), 2732-47.